Table 1.
Characteristics of patients with Hodgkin lymphoma in the SEER database by race and ethnicity (n = 22,415), diagnosed 1992–2015.
| Non-Hispanic White | Non-Hispanic Black | Hispanic | Asian/other | p | |
|---|---|---|---|---|---|
| n | 15,025 | 2,513 | 3,424 | 1,453 | |
| Age, year (median [IQR]) | 36 [25, 52] | 34 [25, 47] | 32 [22, 50] | 31 [23, 48] | <0.001 |
| Gender = male, no. (%) | 8,234 (54.8) | 1,354 (53.9) | 1,952 (57.0) | 787 (54.2) | 0.06 |
| Diagnosis year = 2004–2015, no. (%) | 7,386 (49.2) | 1,425 (56.7) | 1,998 (58.4) | 925 (63.7) | <0.001 |
| Yost index (median [IQR]) | 11,477 [11,045–11,604] | 11,259 [10,936–11,556] | 11,050 [10,964–11,551] | 11,567 [11,050– 11,665] | <0.001 |
| Histology, no. (%) | <0.001 | ||||
| cHL, NOS | 2,377 (15.8) | 529 (21.1) | 684 (20.0) | 276 (19.0) | |
| LD | 149 (1.0) | 25 (1.0) | 68 (2.0) | 20 (1.4) | |
| MC | 1,885 (12.5) | 318 (12.7) | 584 (17.1) | 167 (11.5) | |
| LR | 432 (2.9) | 88 (3.5) | 98 (2.9) | 50 (3.4) | |
| NS | 9,515 (63.3) | 1,308 (52.0) | 1,874 (54.7) | 874 (60.2) | |
| NLPHL | 667 (4.4) | 245 (9.7) | 116 (3.4) | 66 (4.5) | |
| Ann Arbor stage, no. (%) | <0.001 | ||||
| Stage I | 3,114 (20.7) | 515 (20.5) | 581 (17.0) | 242 (16.7) | |
| Stage II | 6,457 (43.0) | 868 (34.5) | 1,279 (37.4) | 661 (45.5) | |
| Stage III | 3,027 (20.1) | 559 (22.2) | 743 (21.7) | 269 (18.5) | |
| Stage IV | 2,427(16.2) | 571 (22.7) | 821 (24.0) | 281 (19.3) | |
| Radiotherapy, no. (%) | <0.001 | ||||
| Yes | 6,172 (41.1) | 749 (29.8) | 1,043 (30.5) | 616 (42.4) | |
| No/unknown | 8,853(58.9) | 1,764 (70.2) | 2,381 (69.5) | 837(57.6) | |
| Chemotherapy, no. (%) | 15,025 | 2,513 | 3,424 | 1,453 | <0.001 |
| Yes | 12,022 (80.0) | 1,975 (78.6) | 2,856 (83.4) | 1,194 (82.2) | |
| No/unknown | 3,003 (20.0) | 538 (21.4) | 568 (16.6) | 259(17.8) | |
| Median person-years at risk [IQR] | 12.55 [6.96, 18.71] | 10.92 [5.80,17.05] | 9.30 [4.38, 15.71] | 9.38 [4.80;14.96] | <0.001 |
Categorical variables were compared using Pearson chi-square tests; continuous variables were compared using Kruskal–Wallis H tests.
cHL, classic Hodgkin lymphoma; NOS, not otherwise specified; LD, lymphocyte depleted; MC, mixed cellularity; LR, lymphocyte rich; NS, nodular sclerosing; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; IQR, interquartile range.